Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers

Authors

  • Sihem Sebbagh Department of Medical Oncology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France
  • Julia Roux Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Paris, France
  • Chantal Dreyer Department of Medical Oncology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France
  • Cindy Neuzillet Department of Medical Oncology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France
  • Armand de Gramont Department of Medical Oncology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France
  • Cecilia Orbegoso Department of Medical Oncology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France
  • Olivia Hentic Department of Gastroenterology and Pancreatology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France
  • Pascal Hammel Department of Gastroenterology and Pancreatology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France
  • Aimery de Gramont Institut Hospitalier Franco-Britannique, Levallois-Perret, France
  • Eric Raymond Department of Medical Oncology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France
  • Thierry André Department of Medical Oncology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Paris, France
  • Benoist Chibaudel Institut Hospitalier Franco-Britannique, Levallois-Perret, France
  • Sandrine Faivre Department of Medical Oncology, Beaujon University Hospital, Assistance Publique-Hôpitaux De Paris (AP-HP), Clichy, France

DOI:

https://doi.org/10.1080/0284186X.2016.1191670

Abstract

Background: Gemcitabine (GEM)-platinum chemotherapy stands as first-line therapy for patients with recurrent/advanced biliary tract cancer (BTC), yielding progression-free survival (PFS) of 3.4–6.4 months. No standard second-line chemotherapy after GEM-platinum failure exists and data on survival benefit remain limited.

Material and methods: We retrospectively reviewed patients with recurrent/advanced BTC who received gemcitabine-oxaliplatin (GEMOX)-based chemotherapy followed by 5-fluorouracil-irinotecan (FOLFIRI)-based chemotherapy to evaluate the efficacy of the sequential treatment strategy. Overall survival (OS) and PFS were calculated by Kaplan–Meier method.

Results: Fifty-two patients were analyzed, 21 (40%) had intrahepatic, 14 (27%) had hilar/extrahepatic, and 17 (33%) had gallbladder cancer. Median age was 64 years (range 38–79 years). Prior curative intent resection of the primary tumor was performed in 23 (44.2%) patients and GEMOX adjuvant chemotherapy was given in 12 (23.1%) patients. After a median follow-up of 36.3 months, 47 (90.4%) patients completed the treatment strategy. First-sequence GEMOX and second sequence FOLFIRI achieved 4.8 months and 3.2 months median PFS, respectively. The global OS for the sequential chemotherapy was 21.9 months. The sequence of FOLFIRI resulted in a median OS of 8.4 months.

Conclusion: The sequence of GEMOX-FOLFIRI is a potential treatment strategy for patients with recurrent/advanced BTC.

Downloads

Download data is not yet available.

Downloads

Published

2016-10-02

How to Cite

Sebbagh, S., Roux, J., Dreyer, C., Neuzillet, C., de Gramont, A., Orbegoso, C., … Faivre, S. (2016). Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers. Acta Oncologica, 55(9-10), 1168–1174. https://doi.org/10.1080/0284186X.2016.1191670

Issue

Vol. 55 No. 9-10 (2016): Acta Oncologica

Section

Articles